key: cord-0832209-ynlito8o
authors: Khana, Wahab A.; Barney, Rachael E.; Tsongalis, Gregory J.
title: CRISPR-cas13 enzymology rapidly detects SARS-CoV-2 fragments in a clinical setting
date: 2021-10-28
journal: J Clin Virol
DOI: 10.1016/j.jcv.2021.105019
sha: 2c3c40ae1923e3e3786cb60b7bf5be80a8387368
doc_id: 832209
cord_uid: ynlito8o

BACKGROUND: The well-recognized genome editing ability of the CRISPR-Cas system has triggered significant advances in CRISPR diagnostics. This has prompted an interest in developing new biosensing applications for nucleic acid detection. Recently, such applications have been engineered for detection of SARS-CoV-2. Increased demand for testing and consumables of RT-qPCR assays has led to the use of alternate testing options. Here we evaluate the accuracy and performance of a novel fluorescence-based assay that received EUA authorization for detecting SARS-CoV-2 in clinical samples. METHODS: The Specific High-Sensitivity Enzymatic Reporter UnLOCKing (SHERLOCK) technology forms the basis of the Sherlock CRISPR SARS-CoV-2 kit using the CRISPR-Cas13a system. Our experimental strategy included selection of COVID-19 patient samples from previously validated RT-qPCR assays. Positive samples were selected based on a broad range of cycle thresholds. RESULTS: A total of 60 COVID-19 patient samples were correctly diagnosed with 100% detection accuracy (relative fluorescence ratios: N gene 95% CI 29.9-43.8, ORF1ab gene 95% CI 30.1-46.3). All controls, including RNase P, showed expected findings. Overall ratios were robustly distinct between positive and negative cases relative to the pre-established 5-fold change in fluorescence. CONCLUSIONS: We have evaluated the accuracy of detecting conserved targets of SARS-CoV-2 across a range of viral loads, including low titers, using SHERLOCK CRISPR collateral detection in a clinical setting. These findings demonstrate encouraging results, especially at a time when COVID-19 clinical diagnosis is in demand. This approach highlights new thinking in infectious disease identification and can be expanded to measure nucleic acids in other clinical isolates.

A total of 60 COVID-19 patient samples were correctly diagnosed with 100% detection accuracy (relative 56 fluorescence ratios: N gene 95% CI 29.9-43.8, ORF1ab gene 95% CI 30.1-46.3). All controls, including 57 RNase P, showed expected findings. Overall ratios were robustly distinct between positive and negative 58 cases relative to the pre-established 5-fold change in fluorescence. 59 Conclusions 60 We have evaluated the accuracy of detecting conserved targets of SARS-CoV-2 across a range of viral 61 loads, including low titers, using SHERLOCK CRISPR collateral detection in a clinical setting. These findings 62 demonstrate encouraging results, especially at a time when COVID-19 clinical diagnosis is in demand. 63 This approach highlights new thinking in infectious disease identification and can be expanded to 64 measure nucleic acids in other clinical isolates.

The novel infectious severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) emerged in 82 Wuhan, China in late 2019 and has since become a global pandemic 1 . From reports of the initial set of 83 infected patients 2-4 , emerging evidence continues to reflect that some individuals experienced severe 84 conditions requiring intensive care and hospitalization with a significant number succumbing to the virus. 85 In the majority of patients, the clinical course typically ranged from marked fever, myalgia, pneumonia to 86 dyspnea and respiratory distress 2-4 . As we learned more about the disease course, it became apparent 87 that most individuals present with mild symptoms, but more importantly, asymptomatic or low-level 88 infected individuals can become carriers who further potentiate the spread of the COVID-19 disease 5,6 . 89 Mitigating the spread of the virus clearly involves accurate, efficient and increased testing with a 90 simultaneous public health surveillance effort. The gold standard test uses quantitative reverse 91 transcriptase polymerase chain reaction (RT-PCR) approach. RT-PCR based approaches for SARS-CoV-2 92 typically require detection of multiple targets. For this, several pre-requisites need to be in place such as 93 having hydrolysis sequence-specific probes that need to be labeled with a distinct fluorescent dye and an 94 appropriate quencher moiety. The emission maxima of the dyes must not overlap with each other and 95 reactions need to be carried out on an appropriate real-time cycler that supports multiplex analysis. 96 Further, for downstream quantification, the efficiency of the method may vary between RT-PCR runs and 97 reactions. Taken together, although PCR is very effective in optimized scenarios, these pre-requisites can 98 limit the use of PCR testing in locations outside central laboratories. Therefore, frequent, rapid, and 99 portable testing is necessary; especially with the already limited resources for RT-PCR based reagents 100 and consumables. This has prompted new strategies for viral RNA detection of SARS-CoV-2. Clustered 101 regularly interspaced short palindromic repeats (CRISPR) can complement RT-PCR testing and provide 102 comparable sensitivity and high specificity. This approach uses guide RNA enzymes from the Cas family (i.e. Cas12, Cas13) that are engineered with a programmable spacer sequence and nucleotide binding 104 domains that can cleave the nucleic acid target of interest 7,8 .

In the current study, we employ the Specific High Sensitivity Enzymatic Reporter UnLOCKing 107 (SHERLOCK) technology that was initially described as a means to rapidly detect nuclei acids in human 108 health applications. In particular, this was applied to instances where different strains of the Zika and 109 Dengue viruses as well as other pathogenic bacteria needed to be distinguished 9,10 It has since been used 110 to identify mutations in cell-free tumor DNA in the background of genomic DNA and has broad 111 applications in genotyping human DNA 9 . The current approach naturally leverages SHERLOCK as a 112 CRISPR-based diagnostic platform to detect SARS-CoV-2 viral RNA. In terms of material cost, the 113 SHERLOCK assay is comparable to RT-PCR and can be further reduced at production scale ($0.60-114 0.70/reaction) 11 . The CRISPR guide RNA is a short RNA sequence that is cheap to synthesize and the 115 quencher has a fixed sequence that does not need to be redesigned and ordered for each new target 12 Of 116 note, the expense for detection platforms such as a fluorescent plate reader and incubator are also lower 117 than purchasing a RT-PCR instrument 12 . The main principal behind SHERLOCK is that in the presence of 118 SARS-CoV-2 viral RNA , a Cas13 enzyme complexed with a virus targeting RNA will be activated and 119 will cleave the viral RNA resulting in collateral RNase activity 7,12 .

The sensitivity and specificity of the assay to detect synthetic SARS-CoV-2 viral RNA was 121 determined by Sherlock Biosciences as part of the emergency use authorization (EUA) and was 122 successfully submitted to the FDA (https://www.fda.gov/medical-devices/coronavirus-covid-19-and-123 medical-devices/sars-cov-2-reference-panel-comparative-data). Each viral RNA target (Nucleocapsid or N 124 gene, Open Reading Frame 1ab or O gene) was tested in triplicate over a range of 10 dilutions. The 125 estimated limit of detection for the N and O target was determined to be 0.9 and 4.5 copies/µL of viral detection, which was determined to be 6.75 copies/µL of VTM from 19 out of 20 samples with a 95% 128 detection rate (https://www.fda.gov/media/137747/download). Here we extend this work and present a 129 clinical evaluation of the SHERLOCK approach in a CLIA-certified molecular diagnostics laboratory 130 performing high complexity testing for detection of SARS-CoV-2. loading onto a pre-warmed multimode plate reader (BioTek Synergy NEO2). All steps were performed in a unidirectional workflow.

Data processing and analysis 184 The specific plate reader configuration settings for initiating the analysis are provided in Fig. 2 . 185 Following the 10-minute sample analysis protocol, raw fluorescence data from each well of the assay Table 1. analysis where the Ct value is inversely proportional to the viral copy number. A total of 43 positive 208 (SARS-CoV-2 detected) and 17 negative samples were analyzed (n = 60 total) using the SHERLOCK 209 Cas13 technology. BioTek Gen5 software clearly demarcated a positive result relative to a negative one with a marked 217 increase in relative fluorescence (Fig. 3) . Ratios calculated from the raw fluorescence values at t 10min for 218 test samples were nearly 45 to 55-fold higher for the N and O gene targets (ratios > 5) respectively for a 219 positive Cas13 detection relative to a negative finding. This further suggests that the collateral cleavage 220 activity of the CRISPR complex is robust at differentiating infected from non-infected patients in our 221 cohort with high accuracy. All positive, negative, and internal extraction control -RP; performed as 222 expected with normalized fluorescence ratios well below a 3-fold increase cut-off for the NTC ( Table 2) . Table 3 ) and detection accuracy 100% 242 compared to the gold standard. A major advantage of CRISPR based diagnostics is that it is highly 243 specific, because the Cas13a RNase remains dormant until it binds to its specific programmed RNA target 244 16 . One limitation of the current work is that it was performed in a smaller subset of clinical samples that 245 were available with a focus towards evaluating sample concordance with RT-PCR. However, given that 246 reagents volumes are amenable to being scaled and guide RNAs cheaply designed; this assay has the 247 potential for higher throughput testing capacity. This assay, termed DETECTR was given EUA status, and examines the N2 portion of the N gene. The Sherlock CRISPR SARS-CoV-2 kit corroborates these findings and expands the repertoire of viral 258 genomic analyses to the Cas13 CRISPR-Cas effector family using fluorescence-based detection. By 259 contrast to the DETECTR assay, the SHERLOCK approach used in the current study examined two 260 SARS-CoV-2 gene targets (N and ORF1ab). Overall Sherlock's CRISPR SARS-CoV-2 kit exhibited a 261 limit of detection down to 6.75 copies/µL, as mentioned above, and had an approximate process time of 262 50 minutes.

As advances in COVID-19 diagnostics emerge, CRISPR testing, because of its many advantages, 264 will be at the forefront. 12,16 . This is further underscored by the 2020 Nobel prize recently awarded towards 265 this disruptive technology that has made scientific history 20,21 . In the context of the current work, 266 SHERLOCK technology is also poised to rapidly detect SARS-CoV-2 RNA from other sample matrices.

The COVID-19 pandemic has accelerated CRISPR diagnostics and we are only at the beginning of 268 this revolution. One of the unique features of the SHERLOCK approach applied here is that viral RNA 269 can be directly detected with high accuracy and the CRISPR-Cas13 enzyme is rapidly programmable to 

The authors declare no competing interests.

We thank members of SHERLOCK Biosciences for sharing reagents, initial EUA data, and valuable 

Automated sample preparation for regulated bioanalysis: an integrated multiple 327 assay extraction platform using robotic liquid handling

Overcoming the bottleneck to widespread testing: a rapid review of nucleic acid 329 testing approaches for COVID-19 detection

CRISPR-Cas12a target binding unleashes indiscriminate single-stranded DNase 331 activity

Detection of SARS-CoV-2 with SHERLOCK One-Pot Testing

CRISPR-Cas12-based detection of SARS-CoV-2

Disruptive Technology: CRISPR/Cas-Based Tools 337 and Approaches

Chemistry Nobel Honors CRISPR, an 'Essential' Tool for Cancer

Risk of COVID-19 among front-line health-care workers and the general 341 community: a prospective cohort study

CRISPR-cas systems based molecular diagnostic tool for infectious diseases and 343 emerging 2019 novel coronavirus (COVID-19) pneumonia